Orchard Therapeutics Advances MLD Newborn Screening Legislation in the U.S.
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 7h ago
0mins
Source: Globenewswire
- Importance of Newborn Screening: Newborn screening is the only effective means of diagnosing MLD prior to symptom onset, enabling optimal treatment outcomes for families dealing with this rapidly progressive and fatal disease.
- Legislative Progress: Currently, 14 states have enacted RUSP-aligned legislation covering over 50% of U.S. births, aimed at expediting the addition of newly approved RUSP conditions to their respective newborn screening panels.
- Global Advancement: Community-led efforts are advancing newborn screening for MLD globally, with several states and countries actively evaluating and implementing related policies, reflecting growing international recognition of the need for MLD screening.
- Treatment Opportunities: The FDA has approved the only therapy for early MLD patients, underscoring the critical role of early detection and diagnosis in improving patient outcomes, which will help alleviate emotional and financial burdens on families in the future.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
